amivantamab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antitumor, monoclonal antibodies	5463	2171511-58-1

Description:

Molecule	Description
Molfile Synonyms: amivantamab amivantamab-vmjw rybrevant JNJ-6372 JNJ 61186372 CNTO4424	Amivantamab-vmjw is a bispecific antibody that binds to the extracellular domains of EGFR and MET. In in vitro and in vivo studies amivantamab-vmjw was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity ( ADCC) and trogocytosis mechanisms, respectively. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

amivantamab
amivantamab-vmjw
rybrevant
JNJ-6372
JNJ 61186372
CNTO4424

Amivantamab-vmjw is a bispecific antibody that binds to the extracellular domains of EGFR and MET. In in vitro and in vivo studies amivantamab-vmjw was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity ( ADCC) and trogocytosis mechanisms, respectively.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 12, 2021	EMA	Janssen-Cilag International N.V.
May 21, 2021	FDA	JANSSEN BIOTECH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infusion related reaction	96.97	48.21	40	328	245481	63243173
Paronychia	53.35	48.21	11	357	5554	63483100

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infusion related reaction	96.86	65.43	28	202	53029	34903672

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Infusion related reaction	80.78	45.43	36	488	230201	79513663
Pulmonary embolism	63.76	45.43	28	496	171626	79572238
Dermatitis acneiform	50.70	45.43	12	512	9981	79733883
Pneumonitis	47.41	45.43	17	507	60843	79683021

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FX18	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES Other monoclonal antibodies and antibody drug conjugates
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations	indication	703228009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	ANTIBODY BINDING	Kd	8.84		DRUG LABEL	DRUG LABEL
Hepatocyte growth factor receptor	Kinase	P08581	MET_HUMAN	ANTIBODY BINDING	Kd	10.40		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
0JSR7Z0NB6	UNII
D11894	KEGG_DRUG
C5446297	UMLSCUI
CHEMBL4297774	ChEMBL_ID
DB16695	DRUGBANK_ID
11030	INN_ID
C000718215	MESH_SUPPLEMENTAL_RECORD_UI
10505	IUPHAR_LIGAND_ID
018739	NDDF
1162751008	SNOMEDCT_US
1162897004	SNOMEDCT_US
4040533	VANDF
4040534	VANDF
2549198	RXNORM
346603	MMSL
39540	MMSL
d09748	MMSL

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Rybrevant	HUMAN PRESCRIPTION DRUG LABEL	1	57894-501	INJECTION	350 mg	INTRAVENOUS	BLA	29 sections
Rybrevant	HUMAN PRESCRIPTION DRUG LABEL	1	57894-501	INJECTION	350 mg	INTRAVENOUS	BLA	29 sections